ILMN vs. BIO, AVTR, BIO.B, GEHC, CNC, ALC, BNTX, SGEN, RMD, and ABC
Should you be buying Illumina stock or one of its competitors? The main competitors of Illumina include Bio-Rad Laboratories (BIO), Avantor (AVTR), Bio-Rad Laboratories (BIO.B), GE HealthCare Technologies (GEHC), Centene (CNC), Alcon (ALC), BioNTech (BNTX), Seagen (SGEN), ResMed (RMD), and AmerisourceBergen (ABC). These companies are all part of the "medical" sector.
Illumina vs.
Illumina (NASDAQ:ILMN) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking.
Illumina has a net margin of -96.12% compared to Bio-Rad Laboratories' net margin of -129.66%. Bio-Rad Laboratories' return on equity of 4.59% beat Illumina's return on equity.
88.0% of Illumina shares are owned by institutional investors. Comparatively, 64.4% of Bio-Rad Laboratories shares are owned by institutional investors. 0.1% of Illumina shares are owned by company insiders. Comparatively, 27.4% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Illumina has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.
Illumina presently has a consensus target price of $249.40, suggesting a potential upside of 13.36%. Bio-Rad Laboratories has a consensus target price of $664.75, suggesting a potential upside of 44.27%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Bio-Rad Laboratories is more favorable than Illumina.
Bio-Rad Laboratories has lower revenue, but higher earnings than Illumina. Illumina is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.
In the previous week, Illumina had 1 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 18 mentions for Illumina and 17 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.52 beat Illumina's score of 0.06 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.
Illumina received 710 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. Likewise, 66.69% of users gave Illumina an outperform vote while only 64.74% of users gave Bio-Rad Laboratories an outperform vote.
Summary
Illumina beats Bio-Rad Laboratories on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ILMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Illumina Competitors List
